Abstract:5564 Background: Although the clinical application of PARP inhibitors (PARPis) has brought great survival benefits to patients with high-grade serous ovarian carcinoma (HGSOC), its resistance has gradually become a major challenge for clinicians with the widespread use of PARPis. Unfortunately, there are no effective, non-invasive means for monitoring PARPis resistance in time during maintain therapy. Methods: We collected peripheral blood samples (n = 37) from 37 healthy subjects and a series of longitudinal peripheral blood samples (n = 61) of 25 platinum-sensitive HGSOC patients undergoing Olaparib maintenance therapy. The genome of white blood cell and cfDNA in plasma was extracted for germline and somatic mutation detection by Circular Ligation Amplification and sequencing (CLAmp-seq) based on a targeted 42-gene panel, respectively. Before cfDNA mutation analysis, background noise introduced by random NGS error was removed and clonal hematopoietic mutations were filtered. Variant-supporting reads > 2 and without germline mutations were defined as the criterion for somatic mutations. Progression-free survival (PFS) was collected through regular follow-up. We analyzed the dynamic changes of cfDNA mutation profiles, the correlation between cfDNA mutations and the prognosis of patients, and screened specific mutation sites that closely associated with Olaparib resistance. Results: The elevation of maximum mutant allele frequency (Max MAF) in cfDNA during Olaparib maintenance therapy predicted a poor prognosis of patients ( P = 0.0043). Pathogenic germline mutations in BRCA1/2 or RAD51 were strongly associated with longer PFS ( P = 0.0229) and acquired new MRE11A mutations significantly shortened the PFS in patients ( P = 0.0005). Dynamic fluctuations of somatic mutation sites in CHEK2:p.K373E ( P = 0.0091) and CHEK2:p.R406H ( P = 0.0002) can be used to evaluate the therapeutic efficacy of patients. Remarkably, MRE11A:p.K464R may be a vital driving factor of Olaparib resistance and all patients who acquired new MRE11A:p.K464R in post-treatment cfDNA developed resistance to Olaparib and had significantly shorter PFS than those without it ( P = 0.0005). Besides, the combination of CHEK2:p.R406H and acquired new MRE11A:p.K464R in post-treatment improved the predictive efficiency of patients’ prognosis compared with them alone ( P < 0.0001). Conclusions: Olaparib resistance was robustly associated with the mutation load of tumor cells, and analysis of mutation profiles in cfDNA can be accurately monitor the status of Olaparib resistance in patients with HGSOC. Acquired new MRE11A:p.K464R may be a vital driver of Olaparib resistance and is expected to be a target for anti-tumor drug development.

Development and Validation of a Sensitive LC–MS/MS Method for the Assay of Four PARP Inhibitors in Human Plasma and Its Application in Ovarian Cancer Patients

Potential Biomarkers Of Poly (Adp-Ribose) Polymerase Inhibitors For Cancer Therapy

Simultaneous quantification of pirarubicin, doxorubicin, cyclophosphamide, and vincristine in human plasma of patients with non-Hodgkin's lymphoma by LC-MS/MS method.

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

Pamiparib in Patients with Locally Advanced or Metastatic HER2-negative Breast Cancer with Germline BRCA Mutations: a Phase II Study

Breaking the Iron Homeostasis: A “trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition

Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer.

A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer

Potential indicators in circulating cell-free DNA for monitoring PARP inhibitor resistance in high-grade serous ovarian cancer.

Evaluation of the efficacy of marine natural products against PARP-1/2 proteins in high-grade serous ovarian cancer: insights into MD and SMD simulations

A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China

Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations

Pooled Analysis Of Phase I Dose-Escalation And Dose Cohort Expansion Studies Of Imp4297, A Novel Parp Inhibitor, In Chinese And Australian Patients With Advanced Solid Tumors.

577P Updated Analysis of Phase I Dose-Escalation and Dose Cohort Expansion Studies of Senaparib (IMP4297) in Chinese Patients with Advanced Solid Tumours

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

Multidetector CT.

Liquid chromatography–tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma

Adverse events as a potential clinical marker of antitumor efficacy in ovarian cancer patients treated with poly ADP-ribose polymerase (PARP) inhibitor